Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial

卡格列净 医学 耐受性 内科学 不利影响 肾功能 肾脏疾病 糖尿病 2型糖尿病 内分泌学
作者
Amanda Siriwardana,Luke Buizen,Min Jun,Sradha Kotwal,Clare Arnott,Meg Jardine,Adeera Levin,Hiddo J.L. Heerspink,David M. Charytan,Carol A. Pollock,Vlado Perkovic,Brendon L. Neuen
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
标识
DOI:10.1111/dom.16190
摘要

Abstract Aim SGLT2 inhibitors may be underused in older adults with type 2 diabetes due to concerns about safety and tolerability. This pooled analysis of the CANVAS Program and CREDENCE trial examined the efficacy and safety of canagliflozin according to age. Methods Pooled individual participant data from the CANVAS Program ( n = 10 142) and CREDENCE trial ( n = 4401) were analysed by baseline age (<65 years, 65 to <75 years, and ≥75 years). A range of adjudicated clinical outcomes were assessed, including major adverse cardiovascular events and CKD progression, as well as safety outcomes. Cox proportional hazards models and Fine and Gray competing risk analysis were used. Results Among the 14 543 participants, 7927 (54.5%) were <65 years, 5281 (36.3%) were 65 to <75 years and 1335 (9.2%) were ≥75 years. Older participants had higher rates of atherosclerotic cardiovascular disease and heart failure, longer diabetes duration and lower mean eGFR. Reductions in cardiovascular and kidney outcomes with canagliflozin were consistent across age categories (all p trend >0.10), although there was some evidence that effects on cardiovascular death and all‐cause death were attenuated with older age ( p trend = 0.02 and 0.03, respectively). Although the incidence of adverse events increased with age, effects of canagliflozin on safety outcomes including acute kidney injury, volume depletion, urinary tract infections and hypoglycaemia, were not modified by age (all p trend >0.10). Conclusions In patients with varying degrees of kidney function, canagliflozin reduced cardiovascular and kidney outcomes, regardless of age, with no additional safety concerns identified in older patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
JingP完成签到,获得积分10
1秒前
王kk完成签到 ,获得积分10
1秒前
sll完成签到 ,获得积分10
5秒前
白锎水完成签到 ,获得积分10
8秒前
孙文远完成签到,获得积分10
8秒前
刘先生完成签到 ,获得积分10
9秒前
luckweb完成签到,获得积分10
9秒前
韭菜完成签到,获得积分10
10秒前
105完成签到 ,获得积分0
10秒前
10秒前
疯狂乱跳的脉搏完成签到 ,获得积分10
12秒前
luckweb发布了新的文献求助10
13秒前
哎呀完成签到 ,获得积分20
14秒前
xinL完成签到,获得积分10
14秒前
易翼完成签到,获得积分10
15秒前
充电宝的应助被温暖静柏采纳,获得10
17秒前
Candice完成签到,获得积分10
17秒前
KK完成签到,获得积分10
17秒前
完犊子完成签到,获得积分10
20秒前
幸福雨完成签到 ,获得积分10
21秒前
安静的ky完成签到,获得积分10
21秒前
matafeiyan完成签到,获得积分10
22秒前
YAYING完成签到 ,获得积分10
23秒前
零距离完成签到,获得积分10
24秒前
ddzzgz完成签到 ,获得积分10
25秒前
26秒前
28秒前
迷路柠檬完成签到 ,获得积分10
28秒前
卡云上完成签到,获得积分10
31秒前
韭菜盒子完成签到,获得积分10
31秒前
372925abc完成签到,获得积分10
31秒前
Hello的应助被chic采纳,获得20
33秒前
王旭倩完成签到 ,获得积分10
34秒前
Lily完成签到,获得积分10
35秒前
凌风苇岸完成签到 ,获得积分10
38秒前
小雅木子完成签到 ,获得积分10
38秒前
关远航完成签到,获得积分10
39秒前
WQ完成签到,获得积分10
40秒前
以钛的应助被雨品采纳,获得10
41秒前
精明梦柏完成签到,获得积分10
42秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185537
求助须知:如何正确求助?哪些是违规求助? 9574270
关于积分的说明 21834871
捐赠科研通 7783247
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558951
邀请新用户注册赠送积分活动 2481370